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1. Introduction 
Cardiovascular diseases are one of the most common health-care problems throughout the 
world and carry a high rate of mortality (Zannad, et al., 2009). New strategies are urgently 
needed to replace cardiomyocytes and increase circulatory support for the treatment of 
cardiovascular diseases. 
Over the last decade, stem/progenitor-cell therapy has emerged as an innovative approach 
to provide cardiac repair and regeneration (Zimmermann, et al., 2006). Several stem- and 
progenitor-cell types from autologous and allogeneic donors have been analyzed to find the 
most appropriate candidate. Although embryonic stem (ES) cells can differentiate into most 
cardiac cell types (Mummery, et al., 2002) , their clinical use is severely limited due to ethical 
concerns and immunogenic and teratogenic side effects (Blum and Benvenisty, 2008). Adult 
bone marrow-derived stem cells avoid the ethical and clinical issues associated with ES cells 
(Bianco, et al., 2001).  However, animal studies have demonstrated a variable degree of 
cardiomyogenesis, and improvement in heart function by bone marrow-derived stem cells 
(Murry, et al., 2004). Thus, the utility of adult bone marrow-derived stem cells is hampered 
by their limited population size and restricted potential for cardiovascular differentiation 
(Assmus, et al., 2010). 
Recently, therapies based on cardiac progenitor cells (CPC) have emerged as promising 
potential cardiac therapeutics (Gonzales and Pedrazzini, 2009). For cardiovascular therapy, 
pluripotent cardiac progenitor cells (CPCs) resident in the epicardium offer distinct 
advantages over other adult stem-cell types (Wessels and Perez-Pomares, 2004). They are 
autologous, tissue-specific and pre-committed (Dube, et al., 2012) to a cardiac fate, and 
display a greater propensity to differentiate towards cardiovascular lineages (Cai, et al., 
2008), (Smart and Riley, 2012). Epicardial derived cardiac progenitor cells (EPDCs) exist in 
the heart of several species, including mice (Limana, et al., 2007) and humans (van Tuyn, et 
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al., 2007). Due to cardiogenic and angiogenic abilities, epicardial CPCs represent an ideal 
candidate for cardiac regeneration. However, we do not know the mechanisms underlying 
epicardial CPC self renewal, proliferation and differentiation, which are prerequisites for 
cardiac regenerative therapy. An optimal paradigm of cardiovascular therapy may therefore 
consist of identifying the most effective factors that trigger the restoration of epicardial 
CPCs for healing heart injuries, with an emphasis on small molecule-based therapy over 
cell-based therapy. 
It is therefore imperative to obtain a better understanding of the biology and regenerative 
potential of endogenous epicardial CPCs. The race is still on to find the “best” factor or 
drugs to reprogram endogenous epicardial CPCs to reconstitute the myocardium and 
improve function after myocardial damage. 
2. Epicardium as a source of multipotent progenitor cells  
Epicardium derived from proepicardium has an essential modulating role in the differentia-
tion of the compact ventricular layer of the myocardium and the development of cardiac 
vessels during embryogenesis (Zhou, et al., 2008). Deletions of selected genes expressed in 
the epicardium (i.e. VCAM-1, ΅4-integrin) resulted in severe defects in the developing heart 
and its vasculature. The zebrafish epicardium promotes cardiac regeneration through epi-
thelial to mesenchymal transition (EMT) and subsequent migration into the myocardium to 
form neovasculorization (Lepilina, et al., 2006). Signalling from the myocardium to the epi-
cardium (i.e. TΆ4, FOG-2) (Smart, et al., 2007; Tevosian, et al., 2000) also leads undeveloped 
ventricle with vascularisation defects. 
The epicardium through EMT generates a population of Epicardial Derived Progenitor Cells 
(EPDCs) that invade the underlying myocardium, and differentiate into various cardiac 
lineages (Smart and Riley, 2012; Zhou, et al., 2008). Williams Tumour (WT1) gene  has been 
shown to regulate epicardial EMT through beta-catenin (Zamora, et al., 2007) and retinoic 
acid signaling pathways (von Gise, et al., 2011). EPDCs can either form endothelial cells, in 
response to a combination of myocardial vascular endothelial growth factor and basic-
fibroblast growth factor signalling (van Wijk, et al., 2009), or differentiate into smooth muscle 
cells, upon exposure to platelet-derived growth factor (Kang, et al., 2008), transforming 
growth factor beta and bone morphogenetic protein-2 (Sanchez and Barnett, 2012). 
However, TΆ4 (Smart, et al., 2007) and PKR1 (Urayama, et al., 2008) signaling appear to be a 
necessary and sufficient signaling factor for adult EPDC differentiation into the endothelial 
and smooth muscle cells to induce neovascularization. Thymosin beta-4 can activate adult 
epicardial cells (Bock-Marquette, et al., 2009)  acting through reactivation of embryonic 
signalling pathways (Smart, et al., 2007).  
In a regenerative context, the adult epicardial progenitor cell population also mediates 
cardiac repair after injury. TΆ4 can activate adult epicardial cells (Bock-Marquette, et al., 
2009; Smart, et al., 2007) to promote revascularization of the injured mammalian heart by 
forming endothelial and vascular smooth muscle cells. TΆ4 treatment before myocardial 
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infarction alters the responsiveness and fate of activated epicardial cells (WT1+ progenitor 
cells), to differentiate into cardiomyocytes (Smart, et al., 2011). However TΆ4 treatment after 
myocardial infarction induces epicardial expansion and coronary capillary density without 
affecting migration or alteration of WT1+ progenitor cell fate into cardiomyocytes (Zhou, et 
al., 2012).  TΆ4 treatment of mice after MI activates cardiac progenitor cell fate to induce 
cardiomyocyte linage (Bock-Marquette, et al., 2009). However, the cardiac progenitor 
subpopulation remains to be characterized. Further, a sub-population of adult epicardial 
cells retains the potential to give rise to cardiac precursors or endothelial cells (Limana, et 
al., 2007). The regenerative potential of EPDCs has been tested in the injured myocardium. 
The injection of human EPDCs was reported to enhance cardiac repair (Winter, et al., 2007). 
When the cardiomyocyte progenitors were co-transplanted with EPDCs into infarcted 
myocardial tissues, they improved functional repair as compare to single cell type 
supplementation (Zhou, et al., 2011). The effect was shown to be caused by paracrine effects 
from both cell types. Nevertheless, signals and cellular contributions from the EPDCs are 
indispensable for the establishment of normal coronary vasculature and myocardial 
architecture (Smart and Riley, 2012; Winter, et al., 2009). 
3. GPCRs and cardiovascular system 
Many hormones and neurotransmitters use GPCRs to exert their cardiovascular effects 
(Marinissen and Gutkind, 2001; Tang and Insel, 2004). Relatively little information is 
available regarding the role of GPCRs in the functional activities of cardiac 
stem/progenitor cells, both in normal and disease conditions. The well-studied cardiac 
role of GPCRs via Gq signalling (Gutkind and Offermanns, 2009) is to promote cardiac 
hypertrophy (Wettschureck, et al., 2001) or protect cardiomyocytes against hypoxic insult 
(Nebigil, et al., 2003). G12 signaling can interact with the cytoplasmic domain of cadher-
ins (Kaplan, et al., 2001), resulting in the release of the transcriptional activator -catenin. 
G13 signaling is involved in vessel formation (Offermanns, et al., 1997). Gs signaling 
regulates heart rate and contractility in response to catecholamine stimulation, but exces-
sive Gs signaling in heart eventually induces myocardial hypertrophy, fibrosis and ne-
crosis (Gaudin, et al., 1995). Given the important roles of GPCRs in cardiac regulation, a 
key question is how many different GPCRs exist in the heart and what is their physiologic 
significance? Since forty percent of these GPCRs represent viable drug targets (Schlyer 
and Horuk, 2006) and also many of GPCR is involved in regulating cardiovascular sys-
tem, unraveling of novel GPCR in cardiac progenitor/stem cells is very important to de-
velop novel therapies for limit cardiovascular disease. 
3.1. Prokineticins and cognate receptors:  
Prokineticins are structurally homologues of amphibian or reptilian peptide toxins (Kaser, 
et al., 2003). They were first identified in the gastrointestinal tract  as potent agents 
mediating muscle contraction (Hoogerwerf, 2006; Li, et al., 2001), and have been isolated 
from bovine milk (Masuda, et al., 2002) .  They comprise two classes: Prokineticin-1 (PK1), 
originally called endocrine gland-derived vascular endothelial growth factor (EG-VEGF) 
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(LeCouter and Ferrara, 2002) based on the functional similarity to VEGF and prokineticin-
2 (PK2, also called Bv8). PK1 and PK2 are approximately 50% homologous and contain 
carboxyl-terminal cysteine-rich domains that form five disulfide bridges (Bullock, et al., 
2004). N terminal hexapeptide (AVITGA) and cysteine residues in the carboxy-terminal 
domain are crucial for their biological activities . Prokineticins and their receptor  are 
widely distributed in mammalian tissues (Soga, et al., 2002). Prokineticins induce cell 
excitability such as gut spasmogen (Wade, et al., 2009), pain sensitization (Negri, et al., 
2006), circadian rhythm (Li, et al., 2006), and sleep (Hu, et al., 2007)). They also induce cell 
motility  such as angiogenesis (LeCouter and Ferrara, 2002), neurogenesis (Ng, et al., 
2005), hemotopoiesis (LeCouter, et al., 2004),  neovasculogenesis (Urayama, et al., 2008). 
Prokineticins regulate complex behaviors such as feeding (Negri, et al., 2004), drinking 
(Negri, et al., 2004), anxiolity (Li, et al., 2009). Moreover, prokineticins are potent 
survival/mitogenic factors for various cells including endothelial cells , neuronal cells 
(Kisliouk, et al., 2005; Ngan, et al., 2007a), lymphocytes, hematopoietic stem cells 
(LeCouter, et al., 2004), and cardiomyocytes (Nebigil, 2009). Table 1 summarize the 
involvement of prokineticin in the diseases. 
Prokineticins bind to two cognate 7-transmembrane G-protein-coupled receptors. PKR1 and 
PKR2 share about 85% amino acid identity and encoded within distinct chromosomes in 
both mouse and human (Masuda, et al., 2002). Prokineticin-2 is the most potent agonist for 
both receptors (Masuda, et al., 2002). PKR2 is the dominant receptor in the adult brain, 
particularly in the hypothalamus, the olfactory ventricular regions, and the limbic system. 
However, PKR1 is widely distributed in the periphery. These receptors couple to Gq, Gi 
and Gs to mediate intracellular calcium mobilization, activation of MAPK, Akt kinases and 
cAMP accumulation, respectively (Ngan and Tam, 2008). Although prokineticin signaling 
has been implicated as a survival/mitogenic factor for various cells including endothelial 
cells (Guilini, et al., 2010), neuronal cells (Ngan, et al., 2007b), enteric neural crest cells 
(Ngan, et al., 2007a), granulocytic (Giannini, et al., 2009)and monocytic lineage (Dorsch, et 
al., 2005) , lymphocytes and hematopoietic stem cells (LeCouter, et al., 2004), until recently, 
little was known about the underlying molecular and cellular events to regulate 
cardiovascular function. 
3.1.1. A novel role for prokineticin in regulating cardiovascular system  
PK2/PKR1 signaling pathway seems an important cardiovascular regulatory pathway, be-
cause of the following aspects: Prokineticins are potent angiogenic factors (LeCouter and 
Ferrara, 2003), which have beneficial effects on cardiac repair by inducing angiogenesis to 
improve coronary circulation or regenerating the cardiomyocytes (Bellomo, et al., 2000). 
They exert their biological effects via activating GPCRs that couple to diverse G proteins. 
Mutations in the gene encoding prokineticin-2 cause Kallmann syndrome (hypogonado-
tropic hypogonadism) in human (Abreu, et al., 2008; Canto, et al., 2009; Cole, et al., 2008), 
with congestive heart failure and dilated cardiomyopathy. Prokineticins induce differentia-
tion of murine and human bone marrow cells into the monocyte/macrophage lineage and 
activate monocyte proliferation, differentiation and macrophage migration (Denison, et al., 
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2008; Dorsch, et al., 2005; Giannini, et al., 2009). In human end-stage failing heart samples, 
reduced PKR1 and prokineticin-2 transcripts and protein levels implicate a more important 
role for PK2/PKR1 signaling in heart (Urayama, et al., 2007). Therefore, we reasoned that 
PK2/PKR1 signaling should contribute to heart repair by inducing angiogenesis or repairing 
cardiomyocytes. 
3.1.2. Role of PKR1 signaling in cardiovascular system 
In cultured capillary endothelial cells derived from heart, PK2 via PKR1 induces prolifera-
tion, migration and vessel-like formation, activating G11/MAPK and Akt kinases (Guilini, 
et al., 2010). In cardiomyocytes, activation of overexpression of PKR1 protects cardiomyo-
cytes against hypoxic insult, activating the PI3/Akt pathway (Urayama, et al., 2007).  
Transient PKR1 gene transfer after coronary ligation in the mouse model of myocardial 
infarction reduces mortality and preserves heart function by promoting cardiac angiogen-
esis and cardiomyocyte survival. This result suggests that PKR1 may represent a novel 
therapeutic target to limit myocardial injury following ischemic events (Urayama, et al., 
2007).  
Transgenic mice overexpressing PKR1 specifically in the heart under the control of cardiac 
΅-myosin heavy chain (΅-MHC) promoter displayed no spontaneous abnormalities of car-
diomyocytes, but showed increased neovascularisation (Urayama, et al., 2008). Thus, these 
data suggest that PKR1 is involved in post-natal de novo vascularization, rather than vascu-
logenesis during embryogenesis.  
Genetic inactivation of PKR1 in mice (PKR1-knockout mice) exhibit dilated cardiomyopathy 
and reduced angiogenesis in heart (Boulberdaa, et al., 2011). The heart pathology in PKR1 
knockout mice is due to increased apoptosis in cardiomyocytes and reduced epicardial 
progenitor cell numbers. These data was consistent with an endogenous role of PKR1 signal-
ling in stimulating epicardial progenitor cell proliferation and differentiation. All together 
these findings show that PKR1 signalling is involved in regulating cardiomyocyte survival 
signalling, and progenitor cell proliferation and differentiation. 
3.1.3. Role of PKR2 signaling in cardiovascular system  
Since PKR1 and PKR2 are 85% identical and are both expressed in cardiovascular tissues, 
PKR2 may also contribute to cardiomyocyte growth and vascularization. Transgenic mice 
overexpressing PKR2 specifically in the heart under the control of cardiac (΅-MHC) 
promoter exhibit eccentric hypertrophy in an autocrine regulation and impaired 
endothelial integrity in a paracrine regulation without inducing angiogenesis (Urayama, 
et al., 2009). These transgenic PKR2 mice may provide a new genetic model for heart 
diseases. We found that in the endothelial cells PKR2 couples to G12 signaling pathway 
and downregulates ZO-1, thereby inducing endothelial cell fenestration (Urayama, et al., 
2009). 
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3.1.4. Prokineticin signaling in cardiac stem/progenitor cell activation  
Prokineticin-2 has been shown to modulate mobilization of bone morrow-derived cells and 
also promote angiogenesis. Systemic exposure to prokineticins promoted the survival of 
hematopoietic cells and enhanced progenitor mobilization (LeCouter, et al., 2004). Recently, 
we found that prokineticin-2 induces significant outgrowth from mouse epicardial explants 
and quiescent EPDCs, restoring epicardial pluripotency and triggering differentiation of 
endothelial and vascular smooth muscle cells (Urayama, et al., 2008). Co-culturing EPDCs 
with cardiomyocytes overexpressing PKR1 increased prokineticin-2 levels as a paracrine 
factor, thereby promoting EPDC differentiation, mimicking our PKR1-transgenic mice 
model (Urayama, et al., 2008). These prokineticin-2 effects were abolished in EPDC derived 
from PKR1-null mutant hearts, demonstrating PKR1 involvement. Prokineticin/PKR1 
signaling can reprogram adult EPDCs to induce neovascularization. These studies provided 
novel insight for possible therapeutic strategies aiming at restoring pluripotency of adult 
EPDCs to promote neovasculogenesis, by induction of cardiomyocyte- PKR1 signaling. 
Whether epicardial-PKR1 signaling contributes cardiomyocyte function and metabolism, 
and it determines lineage choice decision in EPDCs remained to be investigated. 
 
 
 
Figure 1. Role of prokineticin PKR1 signaling in cardiac regeneration.  
PKR1 signaling protects cardiomyocyte against hypoxia-mediated apoptosis,  activates 
endothelial cells for angiogenesis,  activates EPDC differentiation into vasculogenic cell type 
to induce neovascular formation, activates EPDC differentiation into new cardiomyocytes.   
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DOMAIN ROLE/EXPRESSION in human organs REFERENCE 
Reproduction   
Menstrual 
cycle 
Progesterone induces elevation of prokineticin-1 
expression during the secretory phase indicating a 
role of prokineticins and their receptors in 
endometrial vascular function 
(Battersby, et al., 2004) 
 Prokineticin-1 is derived from granulosa lutein cells 
and its synthesis is elevated during the mid- to late 
luteal phase 
(Fraser, et al., 2005) 
 Alteration of prokineticin-1 can induces several 
biochimical abnormalities characterizing eutopic 
endometrium in endometriosis 
(Tiberi, et al., 2009) 
Placentation 
and pregnancy 
Prokineticin-1 and PKR1 expression is elevated in 
human decidua during early pregnancy. 
Prokineticin-1 via PKR1 regulates expression of host 
implatation-related gene. 
(Evans, et al., 2008) 
 Dysregulation of Prokineticin signaling in fallopian 
tube could affect fallopian tube smooth muscle cells 
contractility and embryo-tubal transport providing 
a potential cause for ectopic pregnancy 
 
 
 
(Shaw, et al., 2010) 
 Prokineticin-1 and its receptor gene polymorphism 
and haplotype were associated with idiopathic 
recurrent pregnancy loss. These three gene 
contribute to recurent pregnancy loss in the 
Taiwanese Han population 
 
 
 
 
(Su, et al.) 
Kallman 
syndrome 
Insufficient prokineticin signaling leads to abnormal 
development of the olfactory system and 
reproductive axis in man 
(Dode, et al., 2006) 
 Mutation in prokineticin-2 and PKR2 genes underlie 
both Kallman sydrome and idiopathic 
hypogonadotropic hypogonadism 
(Cole, et al., 2008) 
 
Behaviour 
Prokineticin-2 may play a role in the 
pathophysiology of mood disorders in the Japanese 
population 
(Kishi, et al., 2009) 
 Prokineticin-2 may play a role in the 
pathophysiology of methamphetamine dependance 
in the Japanese population 
(Kishi, et al., 2010) 
       
Cancer Prokineticins and their receptors are expressed in 
human prostate and their levels increased with 
prostate malignancy 
(Pasquali, et al., 2006) 
 Prokineticin-1 favors neuroblastoma progression  (Ngan, et al., 2007b) 
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DOMAIN ROLE/EXPRESSION in human organs REFERENCE 
 Prokineticin-1 derived from islet and/or pancreatic 
stellate cells act through its receptor on endothelial 
cells to increase angiogenesis in pancreatic disease
 Prokineticin-2 play a role in pathophysiological in 
human tumors and inflammatory disorders 
(Zhong, et al., 2009) 
 Prokineticin-1 is significantly increased in papillary 
thyroid cancer and its expression in papillary 
thyroid cancer is related to BRAF oncogen
(Pasquali, et al., 2011) 
   
Vascular Prokineticin-2 is involved in immune and 
inflammatory response at abdominal aortic 
aneurysms site
(Choke, et al., 2009) 
   
Inflammation Prokineticin-1 was found in the controls in the 
patients with temporomandibular joint disorders 
(Herr, et al.) 
    
Cardiology Prokineticin-2 and PKR1 were reduced in human 
end stage failure heart sample
(Urayama, et al., 2007) 
Table 1. Involvement of prokineticins in human diseases 
4. Conclusion  
All together these data showed that PK2 via PKR1 signaling has important roles on heart 
physiology and pathophysiology. PKR1 is involved in postnatal cardiac vascularization by 
activating epicardial progenitor cells. These studies also raise numerous questions for fur-
ther investigation. Do EPDCs differentiate into functional (beating) cardiomyocytes in vitro 
or in vivo? Do EPDCs differentiate into cardiac lineages in vivo in the damaged adult? Does 
the activity or potential of EPDCs decline with age? The identification of factors which stim-
ulate endogenous cardiac progenitor cells to induce neovascularization and cardiomyocyte 
replacement is an evolving paradigm towards therapeutic intervention in cardiac diseases. 
The race is to facilitate drug discovery for targets acting on cardiomyocytes or EPDCs to 
invoke new coronary vessels and cardiac tissues as a significant step toward cardioprotec-
tion and cardiovascular regeneration. 
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